U.S. Markets open in 5 hrs 26 mins

CymaBay Therapeutics Stock Plunged. Here’s Why It Could Be Time to Buy

Josh Nathan-Kazis

The small-cap biotech company released disappointing trial data on Tuesday, triggering a selloff. Raymond James analyst Steven Seedhouse says the stock is now a Strong Buy.